Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus DOXY LEMMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus DOXY LEMMON.
AUREOMYCIN vs DOXY-LEMMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
100 mg orally or intravenously every 12 hours on day 1, then 100 mg orally or intravenously once daily.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life: 18-22 hours (mean ~20 hours) in adults with normal renal function. Clinically, this supports twice-daily dosing; prolonged in severe renal impairment (up to 40-60 hours) or hepatic impairment.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal (approx. 40% as unchanged drug via glomerular filtration), biliary/fecal (approx. 60% as active and inactive metabolites, with significant enterohepatic recycling). Dose adjustment not required in mild renal impairment, but caution in severe hepatic dysfunction.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic